Rakuten Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

Rakuten Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57	Hold	1	–	–	﹤0.01%	889
2026 Q1	$56	Sell	1 -4	-80%	-$233	﹤0.01%	857
2025 Q4	$297	Sell	5 -56	-92%	-$3.05K	﹤0.01%	795
2025 Q3	$3.3K	Buy	61 +45	+281%	+$2.57K	﹤0.01%	578
2025 Q2	$880	Sell	16 -31	-66%	-$1.82K	﹤0.01%	676
2025 Q1	$3.32K	Buy	47 +27	+135%	+$1.82K	﹤0.01%	534
2024 Q4	$1.31K	Sell	20 -1,240	-98%	-$83.1K	﹤0.01%	604
2024 Q3	$88.6K	Buy	1,260 +1,259	+125,900%	+$105K	0.04%	139
2024 Q2	$82	Hold	1	–	–	﹤0.01%	683
2024 Q1	$87	Hold	1	–	–	﹤0.01%	684
2023 Q4	$96	Buy	+1	New	+$88	﹤0.01%	586

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Rakuten Securities's BMRN Position: Q2 2026 in Review

Rakuten Securities held its BioMarin Pharmaceuticals (BMRN) position steady in Q2 2026 at 1 share worth $57. The position accounts for ﹤0.01% of the portfolio, ranked #889.

Rakuten Securities first reported a position in BMRN in Q4 2023 and has held it in 11 quarters since. The position peaked at $88.6K in Q3 2024. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Rakuten Securities held 1 share of BioMarin Pharmaceuticals worth $57 as of Q2 2026.
Rakuten Securities left its BioMarin Pharmaceuticals share count unchanged in Q2 2026.
BioMarin Pharmaceuticals made up ﹤0.01% of Rakuten Securities's portfolio in Q2 2026, its #889 holding.
Rakuten Securities first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Rakuten Securities's BioMarin Pharmaceuticals position peaked at $88.6K in Q3 2024.
561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Rakuten Securities's 13F filing for Q2 2026, filed 12 Aug 2026.